Device Trial Radar · NCT07946224
Comparison of Breast Acoustic CT and Automated Breast Ultrasound in Women With Unilateral Untreated Breast Cancer
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Jan 2027
Primary completion
Jan 2029
Study completion Jan 2029
Sponsor
- Lead sponsor
- Stanford UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- QT Imaging Holdings, Inc.
- First posted
- Nov 18, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated device
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study addresses an unmet need to improve the diagnostic accuracy of: 1. supplemental breast cancer screening with whole breast US and 2. the evaluation of disease extent in women with newly diagnosed breast cancer.
Conditions
- Breast Cancer
Interventions
QT Scanner: Quantitative Transmission Ultrasound Breast Imaging SystemDevice
QT: The scanner is an FDA-cleared imaging technology that uses transmission ultrasound to generate quantitative maps of breast tissue properties (e.g., speed of sound, absorption) as well as provides reflection ultrasound images. It is a non-invasive, non-ionizing imaging modality and does not involve administration of a drug or biologic. Each participant will undergo one (1) imaging examination using the QT Scanner for comparison with images obtained using automated breast ultrasound (ABUS)
ABUS: Invenia™ ABUS, Invenia Automated Breast Ultrasound System, ABUS, GE ABUSDevice
ABUS is FDA-approved for both supplemental breast cancer screening in women with radiographically dense breast tissue, and for diagnostic breast ultrasound imaging. Each participant will undergo one ABUS imaging examination for comparison with images obtained using the investigational QT Scanner.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Additional Breast Cancer Lesions DetectedTime frame: Baseline
- BI-RADS AssessmentTime frame: Baseline
- Numerical Likelihood of MalignancyTime frame: Baseline
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Stanford University
Palo Alto, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.